Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity

SIMPLE SUMMARY: The era of immune checkpoint blockade (ICB) with nivolumab and pembrolizumab (anti-PD-1) alone or in combination with ipilimumab (anti-CTLA-4) has led to prolonged survival in patients with cutaneous melanoma (CM). However, the response to ICB is low in patients with uveal melanoma (...

Descripción completa

Detalles Bibliográficos
Autores principales: Koch, Elias A. T., Petzold, Anne, Wessely, Anja, Dippel, Edgar, Gesierich, Anja, Gutzmer, Ralf, Hassel, Jessica C., Haferkamp, Sebastian, Kähler, Katharina C., Knorr, Harald, Kreuzberg, Nicole, Leiter, Ulrike, Loquai, Carmen, Meier, Friedegund, Meissner, Markus, Mohr, Peter, Pföhler, Claudia, Rahimi, Farnaz, Schadendorf, Dirk, Schell, Beatrice, Schlaak, Max, Terheyden, Patrick, Thoms, Kai-Martin, Schuler-Thurner, Beatrice, Ugurel, Selma, Ulrich, Jens, Utikal, Jochen, Weichenthal, Michael, Ziller, Fabian, Berking, Carola, Heppt, Markus V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833453/
https://www.ncbi.nlm.nih.gov/pubmed/35158786
http://dx.doi.org/10.3390/cancers14030518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833453/
https://www.ncbi.nlm.nih.gov/pubmed/35158786
http://dx.doi.org/10.3390/cancers14030518

Ejemplares similares